Item 7.01 Regulation FD Disclosure.

On May 19, 2022, Krystal Biotech, Inc. (the "Company") presented new data entitled "GEM-3: Phase 3 Safety and Immunogenicity Results of beremagene geperpavec (B-VEC), an Investigational, Topical Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)"at the Society for Investigative Dermatology ("SID") 2022 Annual Meeting in Portland, Oregon. A copy of the poster presented at the SID meeting and the ePoster presentation to be used at the SID meeting are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. The poster and ePoster presentation will also be available on the "Investors" section of the Company's website at www.krystalbio.com.

This information in this Item 7.01 of this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.
  Exhibit
    No.           Description

   99.1             Poster titled "GEM-3: Phase 3 Safety and Immunogenicity Results of beremagene
                  geperpavec (B-VEC), an Investigational, Topical Gene Therapy for Dystrophic
                  Epidermolysis Bullosa (DEB)"
   99.2             ePoster presentation titled "GEM-3: Phase 3 Safety and Immunogenicity Results of
                  beremagene geperpavec (B-VEC), an Investigational, Topical Gene Therapy for
                  Dystrophic Epidermolysis Bullosa (DEB)"
    104           Cover Page Interactive Data file (embedded within the Inline XBRL document)




--------------------------------------------------------------------------------

© Edgar Online, source Glimpses